



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Denisa D. Wagner et al.

Title: Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity

Docket No.: CFBF-P02-015  
Filed: February 19, 2004  
Examiner: Phillip Gambel

Serial No.: 10/782,456  
Due Date: October 21, 2006  
Group Art Unit: 1644

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard and this transmittal document.  
☒ A Response to Restriction Requirement (2 Pages).

Date: 10/10/06

By: William G. Gosz  
William G. Gosz  
Reg. No. 27,787

**Customer No. 56679**  
Gosz and Partners LLP  
450 Bedford Street  
Lexington, MA 02420  
(781) 863-1116

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 10th day of October, 2006.

Denise A. Rose  
Name

Denise A. Rose  
Signature

IFW



Docket No.: CFBF-P02-015

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Wagner et al.

Examiner: Phillip Gambel

Serial No.: 10/782,456

Group Art Unit: 1644

Filed: February 19, 2004

Docket: CFBF-P02-015

Title: METHODS FOR DIAGNOSING AND TREATING HEMOSTATIC  
DISORDERS BY MODULATING P-SELECTIN ACTIVITY

**CERTIFICATE OF FIRST CLASS MAILING**

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 10th day of October, 2006.

*Denise A. Rose*

Denise A. Rose

Commissioner for Patents  
P.O.Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

This is in response to the Office Action of September 21, 2006, in the above-identified patent application.

**Remarks/Arguments** begin on page 2 of this paper.